Analyst InsightsBiotech StocksBloggers Corner 2 Notable Biotech Calls It has not been a good day for investors this Thursday. Worries about trade, the situation in Saudi Arabia, plunging oil prices, falling … Bret Jensen, October 18, 2018
Biotech StocksInsights Uniqure NV (QURE) Is Getting the Street All Fired Up on Its Gene Therapy Candidate in Hemophilia B; Oppenheimer Spotlights Efficacy/Safety Strength Hartaj Singh believes QURE trots out an upper hand advantage with AMT-061. Julie Lamb, October 20, 2017
Biotech StocksStock News Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3 Uniqure NV is back in the race for a hemophilia B gene therapy. Corey Williams, October 19, 2017
Biotech StocksInsights Leerink Sees Uniqure NV (QURE) Pipeline On Track Leerink analyst Michael Schmidt provides a second-quarter recap for shares of Uniqure NV (NASDAQ:QURE), reiterating an Outperform rating with a $27 price target, … Julie Lamb, August 30, 2016
Biotech StocksStock News Company Update (NASDAQ:QURE): Uniqure NV Appoints Jonathan Garen as Chief Business Officer Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr. Corey Williams, July 7, 2016
Biotech StocksStock News Company Update (NASDAQ:QURE): Uniqure NV Announces Results for First Quarter 2016 Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced financial results for the first quarter ending March 31, 2016, and provided a … Corey Williams, May 31, 2016
Biotech StocksStock News Company Update (NASDAQ:QURE): uniQure NV Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT uniQure NV (NASDAQ:QURE), a leader in human gene therapy, announced the data from several preclinical research programs focused on the development and validation … Corey Williams, May 9, 2016
Biotech StocksStock News Stock Update (NASDAQ:QURE): Uniqure NV Announces Results for Fourth Quarter and Financial Year 2015 Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced audited results for the fourth quarter and year ending December 31, 2015, and … Corey Williams, April 4, 2016
Biotech StocksStock News Company Update (NASDAQ:QURE): Uniqure NV Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington’s disease gene therapy … Corey Williams, March 22, 2016
Biotech StocksInsightsMost Popular Analysts Weigh In On Two Rising Biotechs: Dynavax Technologies Corporation (DVAX), Uniqure NV (QURE) While the iShares Nasdaq Biotechnology (IBB) fell nearly 4% today, biotech companies Dynavax Technologies Corporation (NASDAQ:DVAX) and Uniqure NV (NASDAQ:QURE) climbed sharply higher after presenting … Jason Cohen, January 7, 2016
